Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-11-13
1999-01-05
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 21, 4241921, 4241931, 435 691, 435 696, 435 85, 436501, 436518, 530395, A61K 3800, G01N 33566, C07K 200, C12P 2100
Patent
active
058563008
DESCRIPTION:
BRIEF SUMMARY
1. FIELD OF THE INVENTION
In its broadest aspect, the present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type 1, and further comprise ligands for intercellular adhesion molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement receptor type 1, or fragment or derivative thereof, in combination with the Lewis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.
2. BACKGROUND OF THE INVENTION
2.1 THE COMPLEMENT SYSTEM
The complement system is a group of proteins that constitute about 10 percent of the globulins in the normal serum of humans (Hood, L. E., et al., 1984, Immunology, 2d Ed., The Benjamin/Cummings Publishing Co., Menlo Park, Calif., p. 339). Complement (C) plays an important role in the mediation of immune and allergic reactions (Rapp, H. J. and Borsos, T, 1970, Molecular Basis of Complement Action, Appleton-Century-Crofts (Meredity), N.Y.). The activation of complement components leads to the generation of a group of factors, including chemotactic peptides that mediate the inflammation associated with complement dependent diseases. The sequential activation of the complement cascade may occur via the classical pathway involving antigen-antibody complexes, or by the alternative pathway which involves the recognition of foreign structures such as, certain cell wall polysaccharides. The activities mediated by activated complement proteins include lysis of target cells, chemotaxis, opsonization, stimulation of vascular and other smooth muscle cells, and functional aberrations such as degranulation of mast cells, increased permeability of small blood vessels, directed migration of leukocytas, and activation of B lymphocytes and macrophages (Eisen, H. N., 1974, Immunology, Harper & Row Publishers, Inc. Hagerstown, Md., p. 512).
During proteolytic cascade steps, biologically active peptide fragments, the anaphylatoxins C3a, C4a, and C5a (See WHO Scientific Group, 1977, WHO Tech Rep. Ser. 606:5 and references cited therein), are released from the third (C3), fourth (C4), and fifth (C5) native complement components (Hugli, T. E., 1981, CRC Crit, Rev. Immunol. 1:321; Bult, H. and Herman, A. G., 1983, Agents Actions 13:405).
2.2 COMPLEMENT RECEPTORS
COMPLEMENT RECEPTOR 1 (CR1). The human C3b/C4b receptor, termed CR1 or CD35, is present on erythrocytes, monocytes/macrophages, granulocytes, B cells, some T cells, splenic follicular dendritic cells, and glomerular podocytes (Pearon D. T., 1980, J. Exp. Med. 152:20, Wilson, J. G., et al., 1983, J. Immunol. 131:684; Reynes, M., et al., 1976 N. Engl. J. Med. 295:10; Kazatchkine, M. D., et al., 1982, Clin. Immunol. Immunopathol. 27:210). CR1 specifically binds C3b, C4b and iC3b.
CR1 can inhibit the classical and alternative pathway C3/C5 convertases and act as a cofactor for the cleavage of C3b and C4b by factor I, indicating that CR1 also has complement regulatory functions in addition to serving as a receptor (Fearon, D. T., 1979, Proc. Natl. Acad. Sci. U.S.A. 76:5867; Iida, K. I. and Nussenzweig, V., 1981, J. Exp. Med. 153:1138). In the alternative pathway of complement activation, the bimolecular complex C3b,Bb is a C3 enzyme (convertase). CR1 (and factor H, at higher concentrations) can bind to C3b and can also promote the dissociation of C3b,Bb. Furthermore, formation of C3b,CR1 (and C3b,H) renders C3b susceptible to irreversible proteolytic inactivation by factor I, resulting in the formation of inactivated C3b (iC3b). In the classical pathway of complement activation, the complex C4b,2a is the C3 convertase.
CR1 (a
REFERENCES:
patent: 4752569 (1988-06-01), Terasaki et al.
patent: 5081034 (1992-01-01), Bevilacqua et al.
patent: 5164374 (1992-11-01), Rademacher et al.
patent: 5166133 (1992-11-01), Houston et al.
patent: 5212071 (1993-05-01), Fearon et al.
patent: 5227369 (1993-07-01), Rosen et al.
Bevilacqua et al., J. Clin. Invest., 91:379-387 (1993).
Borman, Stu, "Race Is On To Develop Sugar-Based Anti-inflammatory, Antitumor Drugs", C&EN, Dec. 7, 1992, pp. 25-28.
Brustein et al., J. Exp. Med., 176:1415-1419 (1992).
Butcher, Eugene C., Cell, 67: 1033-1036 (Dec. 20, 1991).
Campbell et al., J. Bio. Chem., 259: 11208-11214 (1984).
Goochee et al., Bio/Technology, 9: 1347-1355 (1991).
Howard et al., J. Bio. Chem., 262: 16830-16837 (1987).
Imai et al., Nature, 361: 555-557 (1993).
Kobata et al., Eur. J. Biochem., 209: 483-501 (1992).
Larsen et al., Cell, 59: 305-312 (1989).
Makrides et al., J. Bio. Chem., 267(34): 24754-24761 (1992).
Mulligan et al., J. Clin. Invest., 90: 1600-1607 (1992).
Mulligan et al., J. Immunol., 150(6): 2401-2406 (1993).
Nelson et al., J. Clin. Invest., 91: 1157-1166 (1993).
Norgard et al., Proc. Acad. Sci. USA, 90: 1068-1072 (1993).
Paulson, James C., TIBS, 14: 272-276 (1989).
Phillips et al., Science, 250: 1130-1135 (1990).
Potvin et al., J. Bio. Chem., 265(3): 1615-1622 (1990).
Shandelya et al., Circulation, 87(2): 536-545 (1993).
Sharon et al., Scientific American, pp. 82-88 (Jan. 1993).
Skubitz et al., J. Immunol., 139(5): 1631-1639 (1987).
Stanley et al., J. Bio. Chem., 263(23): 11374-11381 (1988).
Stanley et al., Somatic Cell Genetics, 9(5): 593-608 (1983).
Walz et al., Science, 250:1132-1135 (1990).
Rittershaus Charles W.
Toth Carol A.
Achutamurthy Ponnathapura
Kubinec Jeffrey S.
T Cell Sciences, Inc.
Yankwich Leon R.
LandOfFree
Compositions comprising complement related proteins and carbohyd does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions comprising complement related proteins and carbohyd, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions comprising complement related proteins and carbohyd will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-862348